NCT04983901 2024-11-04
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
M.D. Anderson Cancer Center
Phase 2 Completed
M.D. Anderson Cancer Center
Wake Forest University Health Sciences